Julie Wissink
Internal Medicine · Palo Alto, CANPI 1386738623
Payments from drug & device makers
Across 241 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$808
- AbbVie$727
- Pfizer$702
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$281
- GSK$221
- Merck$214
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,61899%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $808 |
| AbbVie(2 entities) | 35 | $727 |
| Pfizer | 36 | $702 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $281 |
| GSK | 10 | $221 |
| Merck | 10 | $214 |
| Lilly USA, LLC | 9 | $195 |
| Radius Health, Inc. | 6 | $181 |
| CMP Pharma, Inc. | 7 | $163 |
| Teva Pharmaceuticals USA, Inc. | 5 | $130 |
| Boehringer Ingelheim | 6 | $109 |
| Amgen | 4 | $103 |
| Exact Sciences | 4 | $100 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| AstraZeneca | 3 | $55 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| Novartis | 2 | $40 |
| Therapeuticsmd, Inc. | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 1 | $30 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Johnson & Johnson | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$4,653 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $26,095 |
| MounjaroTirzepatide | 13 | $13,928 |
| MyrbetriqMirabegron | 19 | $11,690 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,829 |
| Atorvastatin Calcium | 166 | $2,420 |
| Rosuvastatin Calcium | 57 | $1,864 |
| SynthroidLevothyroxine Sodium | 16 | $1,796 |
| Losartan Potassium | 74 | $980 |
| Levothyroxine Sodium | 73 | $968 |
| Ezetimibe | 32 | $959 |
| Sumatriptan Succinate | 27 | $920 |
| Escitalopram Oxalate | 41 | $820 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 53 | $724 |
| Ipratropium Bromide | 28 | $710 |
| Amlodipine Besylate | 40 | $668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $702 | $26,09526 claims |
| Lilly USA, LLCMounjaro | $195 | $13,92813 claims |
| AstraZenecaSymbicort | $55 | $4,82914 claims |
| AbbVieSynthroid | $727 | $1,79616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Palo Alto
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.